Scarica l'app Stockscreener
4.39
0.90%
-0.04
Dopo l'orario di chiusura:
4.39
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché GDRX Giù?
Forum
Previsione
Precedente Chiudi:
$4.43
Aprire:
$4.42
Volume 24 ore:
1.20M
Relative Volume:
0.83
Capitalizzazione di mercato:
$1.62B
Reddito:
$775.09M
Utile/perdita netta:
$-58.68M
Rapporto P/E:
-33.11
EPS:
-0.1326
Flusso di cassa netto:
$64.06M
1 W Prestazione:
-3.30%
1M Prestazione:
+10.86%
6M Prestazione:
-1.57%
1 anno Prestazione:
-47.68%
Intervallo 1D:
$4.375
$4.50
Intervallo di 1 settimana:
$4.33
$4.67
Portata 52W:
$3.675
$9.2599
Goodrx Holdings Inc Stock (GDRX) Company Profile
Nome
Goodrx Holdings Inc
Settore
Industria
Telefono
(855) 268-2822
Indirizzo
2701 OLYMPIC BOULEVARD, SANTA MONICA
Confronta GDRX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GDRX
Goodrx Holdings Inc
|
4.39 | 1.62B | 775.09M | -58.68M | 64.06M | -0.1326 |
|
VEEV
Veeva Systems Inc
|
281.89 | 46.43B | 2.86B | 780.66M | 1.20B | 4.72 |
|
TEM
Tempus Ai Inc
|
70.11 | 12.01B | 803.32M | -709.10M | -212.68M | -7.8003 |
|
DOCS
Doximity Inc
|
58.51 | 11.00B | 550.17M | 201.35M | 232.07M | 1.00 |
|
HQY
Healthequity Inc
|
100.01 | 9.27B | 1.15B | 96.70M | -161.99M | 1.09 |
|
WAY
Waystar Holding Corp
|
38.33 | 7.03B | 906.14M | -52.62M | 89.62M | -0.3621 |
Goodrx Holdings Inc Stock (GDRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-04 | Iniziato | Mizuho | Neutral |
| 2024-08-09 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2024-05-23 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-05-16 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2024-04-10 | Aggiornamento | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2024-03-25 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2024-03-01 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2024-02-26 | Iniziato | Leerink Partners | Outperform |
| 2024-01-02 | Downgrade | BofA Securities | Buy → Underperform |
| 2023-08-10 | Aggiornamento | DA Davidson | Neutral → Buy |
| 2023-07-31 | Aggiornamento | TD Cowen | Market Perform → Outperform |
| 2022-12-01 | Iniziato | Citigroup | Buy |
| 2022-11-04 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2022-09-16 | Iniziato | KeyBanc Capital Markets | Sector Weight |
| 2022-09-07 | Iniziato | Truist | Hold |
| 2022-08-12 | Iniziato | DA Davidson | Neutral |
| 2022-06-10 | Downgrade | Goldman | Buy → Neutral |
| 2022-06-06 | Ripresa | BofA Securities | Buy |
| 2022-06-01 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2022-05-10 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-05-10 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-05-10 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2022-05-10 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2022-04-11 | Iniziato | Wells Fargo | Equal Weight |
| 2022-04-07 | Iniziato | Guggenheim | Buy |
| 2022-04-01 | Ripresa | Credit Suisse | Neutral |
| 2022-03-15 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2022-03-01 | Reiterato | Barclays | Overweight |
| 2022-03-01 | Reiterato | BofA Securities | Neutral |
| 2022-03-01 | Downgrade | Cowen | Outperform → Market Perform |
| 2022-03-01 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2022-03-01 | Reiterato | Evercore ISI | Outperform |
| 2022-03-01 | Reiterato | Goldman | Buy |
| 2022-03-01 | Reiterato | JP Morgan | Underweight |
| 2022-03-01 | Reiterato | RBC Capital Mkts | Outperform |
| 2022-03-01 | Reiterato | SVB Leerink | Outperform |
| 2022-01-07 | Iniziato | Goldman | Buy |
| 2021-12-21 | Iniziato | Stephens | Overweight |
| 2021-12-02 | Iniziato | Jefferies | Buy |
| 2021-08-31 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2021-08-13 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2021-05-28 | Iniziato | Robert W. Baird | Neutral |
| 2021-04-06 | Ripresa | Evercore ISI | Outperform |
| 2021-01-25 | Iniziato | Guggenheim | Buy |
| 2020-11-19 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-11-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-10-19 | Iniziato | Barclays | Equal Weight |
| 2020-10-19 | Iniziato | BofA Securities | Neutral |
| 2020-10-19 | Iniziato | Citigroup | Buy |
| 2020-10-19 | Iniziato | Cowen | Outperform |
| 2020-10-19 | Iniziato | Credit Suisse | Outperform |
| 2020-10-19 | Iniziato | Deutsche Bank | Hold |
| 2020-10-19 | Iniziato | Goldman | Neutral |
| 2020-10-19 | Iniziato | JP Morgan | Neutral |
| 2020-10-19 | Iniziato | Morgan Stanley | Overweight |
| 2020-10-19 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2020-10-19 | Iniziato | SVB Leerink | Outperform |
| 2020-10-19 | Iniziato | UBS | Buy |
Mostra tutto
Goodrx Holdings Inc Borsa (GDRX) Ultime notizie
GoodRx (GDRX) Launches a New Subscription Service for Erectile Dysfunction Treatment - Insider Monkey
GoodRx launches new subscription service focused on erectile dysfunction treatments - MSN
High Growth Tech Stocks In The US To Watch This June 2025 - simplywall.st
GoodRx (GDRX) Expands Services with New Subscription for ED Trea - GuruFocus
GoodRx (GDRX) Expands Services with New Subscription for ED Treatment | GDRX Stock News - GuruFocus
GoodRx (GDRX) Shares Rise with Launch of Erectile Dysfunction Subscription Service - GuruFocus
GoodRx stock gains on new subscription service (GDRX:NASDAQ) - Seeking Alpha
GoodRx (GDRX) Introduces Subscription Service for ED Treatment | - GuruFocus
GoodRx (GDRX) Introduces Subscription Service for ED Treatment | GDRX Stock News - GuruFocus
GoodRx Launches New Erectile Dysfunction Subscription Service to Simplify Access and Eliminate Treatment Barriers - marketscreener.com
GoodRx (GDRX): Buy, Sell, or Hold Post Q1 Earnings? - Yahoo Finance
GoodRx Launches Community Link to Offer Independent Pharmacies C - GuruFocus
GoodRx Launches Community Link to Offer Independent Pharmacies Cost-Plus Pricing | GDRX Stock News - GuruFocus
GoodRx Launches Community Link to Offer Independent Pharmacies Cost-Plus Pricing - marketscreener.com
GoodRx Disrupts Pharmacy Market with New Cost-Plus Pricing Model for Independent Stores - Stock Titan
GoodRx Launches Community Link to Offer Independent Pharmacies Cost-Plus Pricing – Company Announcement - Financial Times
Jim Cramer Holds Back on GoodRx (GDRX) - MSN
GoodRx: Stabilizing Revenue Amid Healthy Profit Gains - Seeking Alpha
Goodrx Open Sources Lifecycle to Support Innovation in Software Development Velocity and Developer Productivity - marketscreener.com
GoodRx Launches Free Developer Tool That Slashes Testing Time and Infrastructure Costs - Stock Titan
GoodRx Holdings Holds Annual Stockholder Meeting - TipRanks
29,380 Shares in GoodRx Holdings, Inc. (NASDAQ:GDRX) Acquired by Deutsche Bank AG - Defense World
AbCellera Biologics And 2 Other Promising Penny Stocks To Watch - simplywall.st
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Lowers Stake in GoodRx Holdings, Inc. (NASDAQ:GDRX) - Defense World
Head-To-Head Contrast: GoodRx (NASDAQ:GDRX) & Yext (NYSE:YEXT) - Defense World
BNP Paribas Financial Markets Purchases Shares of 39,285 GoodRx Holdings, Inc. (NASDAQ:GDRX) - Defense World
Lazard Asset Management LLC Sells 51,337 Shares of GoodRx Holdings, Inc. (NASDAQ:GDRX) - Defense World
GoodRx Holdings, Inc. (NASDAQ:GDRX) Shares Purchased by Northern Trust Corp - Defense World
GoodRx’s SWOT analysis: prescription savings firm faces pharmacy headwinds - Investing.com
GoodRx to Launch Direct Contracting for Independent Community Pharmacies - marketscreener.com
GoodRx Disrupts Pharmacy Pricing: New Platform Gives Independent Pharmacies Direct Control Over Margins - Stock Titan
GoodRx Holdings, Inc. (NASDAQ:GDRX) Given Average Rating of “Moderate Buy” by Analysts - Defense World
GoodRx Offers Value Proposition As Pharmacy Costs Shifts To Consumers: Analyst - AOL.com
KeyBanc maintains GoodRx stock Overweight with $6 target By Investing.com - Investing.com Nigeria
KeyBanc maintains GoodRx stock Overweight with $6 target - Investing.com
KeyBanc on GoodRx Holdings Inc. (GDRX): 'Attractive Valuation as We Await Continued Execution' - StreetInsider
Demystifying GoodRx Holdings: Insights From 5 Analyst Reviews - Benzinga
UBS Adjusts Price Target for GoodRx (GDRX) Amid Neutral Rating | - GuruFocus
GoodRx Holdings (GDRX) Price Target Lowered by UBS | GDRX Stock News - GuruFocus
The Zacks Analyst Blog Highlights Sprouts Farmers Market, DexCom, Hims & Hers Health, United Natural Foods and GoodRx - TradingView
UBS Adjusts Price Target for GoodRx (GDRX) Amid Neutral Rating | GDRX Stock News - GuruFocus
UBS Adjusts Price Target on GoodRx Holdings to $5.25 From $6, Maintains Neutral Rating - marketscreener.com
Buy 5 Health and Fitness Stocks to Enhance Your Portfolio Returns - TradingView
The Goldman Sachs Group Cuts GoodRx (NASDAQ:GDRX) Price Target to $5.00 - Defense World
Dimensional Fund Advisors LP Raises Stake in GoodRx Holdings, Inc. (NASDAQ:GDRX) - Defense World
Wells Fargo & Company MN Sells 81,454 Shares of GoodRx Holdings, Inc. (NASDAQ:GDRX) - Defense World
GoodRx Holdings First Quarter 2025 Earnings: EPS Misses Expectations - Yahoo Finance
GoodRx Holdings, Inc. (NASDAQ:GDRX) Q1 2025 Earnings Call Transcript - Insider Monkey
GoodRx Holdings (GDRX) Price Target Lowered by Goldman Sachs | G - GuruFocus
Envestnet Asset Management Inc. Takes $84,000 Position in GoodRx Holdings, Inc. (NASDAQ:GDRX) - Defense World
GoodRx Holdings Inc (GDRX) Q1 2025 Earnings Call Highlights: Revenue Growth and Strategic ... - Yahoo Finance
Goodrx Holdings Inc Azioni (GDRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.51%
4.94%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):